Enterprise-wide Disclosures (Tables)

12 Months Ended

Dec. 31, 2012

Enterprise-wide Disclosures [Abstract]

Geographic Area Information

Revenues, including license fees, royalties, grant income, and other revenues by geographic area are based on the country of domicile of the licensee or grantor.

Geographic Area	Revenues for the Year ending December 31,
	2012		2011		2010
Domestic	$	2,529,669	$	3,059,810	$	3,311,211
Asia		1,385,658		1,374,349		396,807
Total revenues	$	3,915,327	$	4,434,159	$	3,708,018

Sources of Revenues

The following table shows the relative portions of BioTime's Hextend® and PentaLyte® royalty and license fee revenues paid by Hospira, CJ, and Summitthat were recognized during the years ended December 31, 2012, 2011, and 2010, the subscription and advertisement revenues, and the OCS, CIRM and QTDP grant incomerecognized during the same periods:

Sources of Revenues	% of Total Revenues for Year ended December 31,
	2012		2011		2010
Hospira		11.0%		14.2%		22.7%
CJ		2.9%		3.5%		6.8%
Summit		3.7%		3.3%		3.9%
CIRM		26.7%		35.4%		42.5%
QTDP		-		-		19.8%
OCS		26.0%		23.0%		-
Others		29.7%		20.6%		4.3%